Multi-Level Degenerative Lumbosacral Spinal Conditions Clinical Trial
Official title:
A Prospective, Randomized, Multi-Center, Open-Label Pilot Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions
| Verified date | June 2024 |
| Source | Medtronic Spinal and Biologics |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is to obtain safety and effectiveness data on the investigational device for multi-level PLF procedures and determine the most appropriate rhBMP-2 dose for use in this indication. The study information may be used for a potential pivotal study design.
| Status | Active, not recruiting |
| Enrollment | 100 |
| Est. completion date | December 2026 |
| Est. primary completion date | April 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 21 Years and older |
| Eligibility | Inclusion Criteria: 1. Degenerative lumbar spine condition: 1. Requiring a PLF procedure using a bilateral metallic screw and rod system in 2-4 consecutive levels from L2-S1; and 2. Diagnosed with: instability (up to and including Grade 2 spondylolisthesis, retrolisthesis, or lateral listhesis), stenosis with documented pre-operative instability, and/or recurrent disc herniation, any of which may have possible concomitant lumbar degenerative deformity (Cobb angle = 30 degrees). 2. Preoperative ODI score =40. 3. Preoperative pain score of =8 (out of 20) on the Preoperative Leg Pain Questionnaire. 4. Most inferior treated spinal level is able to accommodate an interbody fusion device. 5. =21 years of age at the time of signing the informed consent. 6. Failed =6 months non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS). 7. Is willing and able to comply with the study plan and able to understand and sign the Subject Informed Consent Form. Exclusion Criteria: 1. Prior spinal fusion surgical procedure at the involved or adjacent spinal levels. (Prior non-fusion surgery at the target levels, including discectomy and/or single-level foraminotomy or laminectomy, is allowed.) 2. Prior lumbar disc arthroplasty. 3. Significant lumbar instability, defined as sagittal listhesis >Grade 2 at any involved level using Meyerding's Classification or lateral listhesis >25% lateral translation at any involved level. 4. Planned use of an internal or external bone growth stimulator. 5. Lumbar scoliosis >30 degrees. 6. Osteoporosis to a degree that spinal instrumentation is contraindicated or a history of atraumatic vertebral fracture. 7. Morbidly obese, as defined by a Body Mass Index (BMI) >40. 8. Presence of active malignancy or prior history of malignancy. 9. Overt or active bacterial infection, either local or systemic. 10. Has undergone systemic administration of any type of corticosteroid, anti-neoplastic, immunostimulating, or immunosuppressive agents within 30 days prior to implantation of the assigned treatment. 11. Comorbidities precluding subject from being a surgical candidate. 12. History of autoimmune disease known to affect bone metabolism or the spine (e.g., spondyloarthropathies, juvenile arthritis, rheumatoid arthritis, Graves' disease, Hashimoto's thyroiditis). 13. History of any endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta). 14. History of exposure to any recombinant proteins used for bone formation (i.e., Infuse Bone Graft, OP-1 Putty, OP-1 Implant, AUGMENT Bone Graft, GEM21S, i-FACTOR Peptide Enhanced Bone Graft, or PepGen P-15 Synthetic Bone Graft). 15. Hypersensitivity or allergy to any components of the study treatments including, but not limited to, bone morphogenetic proteins (BMPs); injectable collagen; protein pharmaceuticals (e.g., monoclonal antibodies or gamma globulins); bovine collagen products; gentamicin or glycerol (which may be present in trace amounts in the DBM products); and/or instrumentation materials (titanium, titanium alloy, cobalt chrome, cobalt chrome alloy, or polyetheretherketone [PEEK]). 16. History of any allergy resulting in anaphylaxis. 17. Is a prisoner. 18. Is mentally incompetent. If questionable, obtain psychiatric consult. 19. Treatment with an investigational therapy (drug, device, and/or biologic) within 30 days prior to implantation surgery, or such treatment is planned during the 24-month period following implantation of the study treatment. 20. Pregnant or nursing. Females of child-bearing potential must agree not to become pregnant for one year following surgery. 21. Any condition that would interfere with the subject's ability to comply with study instructions, might confound the interpretation of the study, or put the subject at risk. |
| Country | Name | City | State |
|---|---|---|---|
| United States | The Spine Health Institute | Altamonte Springs | Florida |
| United States | Emory University | Atlanta | Georgia |
| United States | Seton Spine & Scoliosis Center | Austin | Texas |
| United States | Indiana Spine Group | Carmel | Indiana |
| United States | University of Virginia | Charlottesville | Virginia |
| United States | University of Virginia Health System | Charlottesville | Virginia |
| United States | The Ohio State University Wexner Medical Center | Columbus | Ohio |
| United States | Spine Colorado | Durango | Colorado |
| United States | Upstate Orthopedics | East Syracuse | New York |
| United States | Fort Wayne Orthopedics | Fort Wayne | Indiana |
| United States | Bronson Methodist Hospital | Kalamazoo | Michigan |
| United States | The University of Kansas (KUMC) | Kansas City | Kansas |
| United States | Beel Medical | Laguna Hills | California |
| United States | New York-Presbyterian Hospital/Columbia University | New York | New York |
| United States | American Neurospine Institute PLLC | Plano | Texas |
| United States | University of California, Davis | Sacramento | California |
| United States | Foundation for Orthopedic Research and Education | Tampa | Florida |
| United States | The Steadman Clinic | Vail | Colorado |
| Lead Sponsor | Collaborator |
|---|---|
| Medtronic Spinal and Biologics |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Radiological Fusion Success | Fusion at each treated level is defined as radiological fusion assessed by radiograph and CT. A subject will be considered a fusion success when the following criteria are met for each treated level:
Bilateral bridging bone (superior transverse process to the inferior transverse process) at each treated level (CT); No more than 3mm translational motion and less than 5 degrees in angular motion at each treated level (flexion/extension radiographs); and Absence of cracking, as evidenced by radiolucent lines completely through the fusion mass (all radiograph views). |
12 months | |
| Secondary | Overall success rate at 12 and 24 months | Overall success is defined as the participant who meet the following five criteria:
Radiographic success, defined as radiological fusion success in the posterolateral space; Pain/disability (ODI) success, defined as at least a 15-point improvement from baseline; Neurological success, defined as maintenance or improvement in neurological status; No SAE related to the PLF grafting material or posterior fixation; and No secondary surgeries classified as a "failure." |
12 and 24 months | |
| Secondary | ODI score at 12 and 24 months | The self-administered Oswestry Disability Index (ODI) Questionnaire (Version 2.1) will be used to assess patient pain and ability to function. The ODI scale ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability). | 12 and 24 months | |
| Secondary | ODI success rate at 12 and 24 months | ODI success is defined as at least a 15-point improvement from baseline. | 12 and 24 months | |
| Secondary | Neurological success rate at 12 and 24 months | Overall neurological success is defined as maintenance or improvement in four key neurological assessments: motor function, sensory function, reflexes, and straight leg raise. In order to be considered a success, each element in the motor, sensory, reflexes, and straight leg raise examinations must remain the same or improve from the time of the preoperative evaluation to the time period evaluated. | 12 and 24 months | |
| Secondary | Back pain score at 12 and 24 months | Numerical rating scales, adapted in part from Measuring Health, will be used to evaluate back pain. The back pain score (0-20) is the summation of pain intensity (0-10) and duration (0-10) scores. | 12 and 24 months | |
| Secondary | Back pain success at 12 and 24 months | Back pain success is defined as at least 30% improvement from baseline. | 12 and 24 months | |
| Secondary | Leg pain score at 12 and 24 months | Numerical rating scales, adapted in part from Measuring Health, will be used to evaluate leg pain. The leg pain score (0-20) is the summation of pain intensity (0-10) and duration (0-10) scores. | 12 and 24 months | |
| Secondary | Leg pain success at 12 and 24 months | Leg pain success is defined as at least 30% improvement from baseline. | 12 and 24 months | |
| Secondary | Radiological fusion success rate at 24 months | Fusion at each treated level is defined as radiological fusion assessed by radiograph and CT. A subject will be considered a fusion success when the following criteria are met for each treated level:
Bilateral bridging bone (superior transverse process to the inferior transverse process) at each treated level (CT); No more than 3mm translational motion and less than 5 degrees in angular motion at each treated level (flexion/extension radiographs); and Absence of cracking, as evidenced by radiolucent lines completely through the fusion mass (all radiograph views). |
24 months | |
| Secondary | AEs related to the PLF grafting material or posterior fixation up to 24 months | A summary of AEs related to the PLF grafting material or posterior fixation up to 24 months. | 24 months | |
| Secondary | Secondary surgeries related to the PLF grafting material or posterior fixation up to 24 months | A summary of secondary surgeries related to the PLF grafting material or posterior fixation up to 24 months | 24 months |